TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Tcr2 Therapeutics Inc Files Prospectus Supplement Related To Offering Of Common Stock Up To $100 Million - SEC Filing
Brief: TCR² Therapeutics Establishes Commercial-Scale Cell Therapy Manufacturing Facility
NASDAQ RESUMED AT 03:27 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:13 PM
Brief: Tcr2 Therapeutics Files For Mixed Shelf Size Not Disclosed
Brief: TCR² Therapeutics Reports Q4 Loss Per Share $0.55
Brief: TCR Therapeutics Announces Commercial Cell Therapy Leader Shawn Tomasello Joins Its Board Of Directors
TCR2 Therapeutics: Falls on $125 mln share offering
Brief: TCR² Therapeutics Announces Proposed Public Offering Of Common Stock
Brief: Tcr2 Therapeutics Inc - Estimates Cash And Cash Equivalents And Investments Were About $228.0 Million As Of December 31, 2020
Brief: Tcr² Therapeutics Announces 2021 Strategic Priorities And Milestones
U.S. RESEARCH ROUNDUP- Arvinas, Phillips 66, Whole Earth Brands
U.S. STOCKS ON THE MOVE-Tesla,Gamida,Solarwinds
TCR2 Therapeutics: Rises on positive data from ovarian cancer therapy study
Brief: Tcr² Therapeutics Reports Third Quarter 2020 Financial Results And Provides Corporate Update
Brief: Tcr² Therapeutics Reports Q2 Loss Per Share Of $0.67
Brief: TCR² Therapeutics Says Public Offering Of 8 Mln Common Shares Priced At $15.50/SHR
Brief: TCR² Therapeutics Announces Proposed Public Offering Of Common Stock